Introduction
While the COVID-19 pandemic highlighted the critical role of gold-standard diagnostic technologies like RT-qPCR, it also exposed significant gaps in global testing infrastructure. Standard laboratory-based tests are often slow, expensive, and reliant on sophisticated equipment, making them difficult to scale in resource-limited settings. Furthermore, most existing point-of-care (POC) diagnostics provide only a binary "positive/negative" result, failing to provide the genomic surveillance data necessary to track the emergence and spread of Variants of Concern (VOCs).
To address these challenges, we developed a robust, multiplexed CRISPR-based detection platform. By utilizing orthogonal Cas13 enzymes and locally manufactured reagents, this assay enables simultaneous COVID-19 diagnosis and variant identification in a format suitable for POC deployment. This approach not only bridges the surveillance gap but also addresses supply chain vulnerabilities in low- and middle-income countries (LMICs).
Methodology
Orthogonal CRISPR Detection
The core of the platform relies on the simultaneous use of two distinct CRISPR-Cas13 enzymes: LwaCas13a and PsmCas13b. These enzymes exhibit "collateral cleavage" activity, where they degrade nearby RNA reporters upon target recognition. Crucially, they possess different cleavage preferences—Cas13a targets poly-U probes, while Cas13b targets poly-A probes. This orthogonality allows the assay to detect two different genetic targets in a single reaction tube without signal interference. In our configuration, one enzyme targets a conserved region of the SARS-CoV-2 N gene for general diagnosis, while the other targets specific mutations in the S gene to identify variants such as Delta (B.1.617.2) or Omicron (B.1.1.529).
Isothermal Amplification and Local Manufacturing
To achieve high sensitivity without thermal cyclers, the assay utilizes Reverse-Transcription Recombinase Polymerase Amplification (RT-RPA). RPA operates at a constant temperature (39–42°C), making it ideal for field use. To ensure sustainability and reduce reliance on expensive proprietary reagents, we successfully "home-brewed" the four primary RPA protein components (UvsX, UvsY, Gp32, and Bsu LF). We demonstrated that these locally produced enzymes perform with equivalent efficiency to commercial counterparts, providing a blueprint for decentralized diagnostic manufacturing.
Stabilization and Readout
For ease of deployment, the reagents were stabilized through lyophilization (freeze-drying) using trehalose as a cryoprotectant. This allows for long-term storage and a simple "just-add-sample" workflow. The results can be interpreted via multiple modalities: fluorescence monitored by a smartphone or a simple LED light box, or colorimetric lateral-flow strips for visual interpretation.
Performance and Validation
The assay underwent rigorous validation using synthetic RNA, cultured viral isolates (including ancestral, Alpha, Delta, and Omicron strains), and 136 clinical nasopharyngeal and throat swabs.
Key performance metrics include:
- High Accuracy: The multiplexed assay demonstrated 100% specificity and 95–97% sensitivity compared to RT-qPCR.
- Sensitivity: The system achieved a Limit of Detection (LoD) comparable to laboratory tests, reliably detecting the virus in samples with Ct values as high as ~37 (approximately 10 copies/µL).
- Variant Specificity: The Delta-specific assay showed no cross-reactivity with other strains. While the Omicron-specific assay was slightly less sensitive (LoD ~34 Ct), it maintained high accuracy across clinical samples.
- Regulatory Milestone: The most sensitive iteration of the freeze-dried assay received full approval from the Thai FDA in September 2021.
Discussion and Future Directions
This platform represents a significant step toward democratizing high-quality molecular diagnostics. By proving that complex, multiplexed CRISPR assays can be produced locally and stored without a cold chain, we offer a sustainable model for pandemic preparedness in LMICs.
While the current protocol primarily utilizes purified RNA, future work will focus on integrating "extraction-free" methods to further simplify the workflow. Additionally, the modular nature of the CRISPR-Cas system allows for rapid reconfiguration; as new variants emerge, the guide RNAs (crRNAs) can be updated with minimal adjustments to the underlying platform. This flexibility ensures that the technology remains relevant for both the ongoing management of COVID-19 and the detection of future infectious disease threats.
Summary updated